SAB Biotherapeutics highlights data in multiple presentations at EASD

SAB Biotherapeutics (SABS) highlighted multiple presentations made at the 61st Annual Meeting of the European Association for the Study of Diabetes held from September 15-19, 2025. The Company had four oral presentations, as well as one invited presentation at an INNODIA-hosted symposium at EASD. On September 15, 2025, Executive Vice President and Chief Medical Officer of SAB BIO, Alexandra Kropotova, M.D., presented at the EASD INNODIA-hosted symposium, “Working to Change the Lives of People Impacted by Type 1 Diabetes Through Unique Disease-Modifying Therapy”, on September 16, 2025, Dr. Kropotova presented “Immunomodulation without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin”, and on September 18, 2025, presented “Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes”. In all three presentations, Dr. Kropotova discussed how SAB-142 demonstrated a clinically validated, multi-specific mechanism of action with sustained immunomodulation in a Phase 1 clinical study. Further, SAB-142 does not cause a sustained lymphodepletion unlike rabbit ATG, which causes a decrease in CD4+ T-cells for up to two years. The Phase 1 study was a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, adaptive design clinical study in 68 healthy volunteers and patients with established T1D. Based on results from the study, SAB-142 has the potential to be a best-in-class T1D immunotherapy. On September 18, 2025, Eric Sandhurst, Ph.D., Director, Program Management, at SAB BIO presented, “Novel Pharmacokinetic Assay for Measuring SAB-142, a Fully Human Anti-Thymocyte Globulin”, showing SAB-142 demonstrates a dose-proportional and reproductible pharmacokinetic profile, as measured by a novel PK assay that was validated for accuracy, precision, selectivity and range. Specifically, the study found that SAB-142 offers the optimal combination of a short PK profile and a sustained immunomodulatory effect out to Day 120 and that there were no major differences in the SAB-142 PK profile between healthy volunteers and T1D patients. Additionally, at EASD, results from the INNODIA-sponsored MELD-ATG study confirmed the disease-modifying potential of rabbit ATG in new-onset Stage 3 autoimmune T1D patients. The trial met its primary endpoint of C-peptide preservation at 12 months with the 2.5 mg/kg dose, while also identifying 0.5 mg/kg as the minimum effective low dose. In addition, a favorable trend in metabolic outcomes was observed with statistically significant results for HbA1C improvement vs. placebo with the minimum effective low dose.